Why the study?
Does myostatin inhibition accelerate muscle degeneration in dysferlin-deficient mice?
Population
Dysferlin-deficient (Dysf(-/-)) mice and dystrophin-deficient (mdx) mice
Design
Preclinical
Key result
Myostatin inhibition in dysferlin-deficient mice initially improved histopathology but ultimately exacerbated muscle degeneration and increased serum CK levels.
Authors
Loading...
Myostatin inhibition may exacerbate degeneration in dysferlin-deficient models; leaves open safety in human muscular dystrophies.
Does myostatin inhibition accelerate muscle degeneration in dysferlin-deficient mice?
Inducing muscle hypertrophy by myostatin blockade in dysferlin-deficient mice exacerbates muscle degeneration, highlighting potential detrimental effects in specific muscular dystrophies.
Lee et al. (2015) studied Dysferlinopathy. Myostatin inhibition (follistatin transgene expression or ACVR2B/Fc) was evaluated on Muscle degeneration and histopathology. Myostatin inhibition in dysferlin-deficient mice initially improved histopathology but ultimately exacerbated muscle degeneration and increased serum CK levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: